Mode
Text Size
Log in / Sign up
Phase 4 N=160 Randomized Quadruple-blind Treatment

Effect of Duloxetine on Opioid Use After Total Knee Arthroplasty

Joint Disease · Pain, Acute · Pain, Chronic

Enrolled (actual)
160
Serious AEs
0.0%
Results posted
Apr 2022
Primary outcome: Primary: Opioid Use — 288; 432.5 Oral Morphine Equivalent (mg)

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Cymbalta (Drug); Placebo (Other)
Age
Adult, Older Adult · 25+ yrs
Sex
All
Sponsor
Hospital for Special Surgery, New York
Primary completion
Dec 2020

Outcome Measures

OutcomeResultp-value
PRIMARY
Opioid Use
288; 432.5
PRIMARY
Pain Scores
4.2; 4.8
SECONDARY
Pain Phenotype
2; 2

Summary

Post-discharge pain after total knee arthroplasty remains problematic; many patients have excessive pain at the 2 week time point (and often thereafter). Reduction in opioid use has become a national goal, due to the 'epidemic' in opioid misuse. In addition to enrolling non-opioid users, we will enroll up to 15 chronic opioid users.

Eligibility Criteria

Inclusion Criteria

  • Age 25 to 75 years
  • Planned use of regional anesthesia
  • Ability to follow study protocol
  • English speaking (Primary outcome obtained via telephone call and secondary outcomes include questionnaires validated in English only)
  • Patients planning on being discharged home or to a rehabilitation center that has agreed to participate

Exclusion Criteria

  • Current Use of duloxetine or other SNRIs, SSRIs, MAOIs, Tricyclic antidepressants, triptans (sumatriptan, rizatriptan, naratriptan, eletriptan, almotriptan, frovatriptan), lithium, buspirone, St. John's Wort
  • Hepatic insufficiency

o Hepatoxicity is reported as a side effect of duloxetine. "Median time to detection of transaminase elevation was about two months" (package insert 5.2

  • Renal insufficiency (ESRD, HD, estimated creatinine clearance < 50 ml/min)
  • Severe CRI may impair duloxetine clearance
  • CLcr=[(140-age (years)] x weight (kg)x0.85 (for female patients)/[72xserum creatinine (mg/dL)]
  • Patients younger than 25 years old and older than 75
  • Patients intending to receive general anesthesia
  • Allergy or intolerance to one of the study medications
  • Patients with an ASA of IV
  • Chronic gabapentin/pregabalin use (regular use for longer than 3 months)
  • Patients with major prior ipsilateral open knee surgery.
  • Chronic opioid use (taking opioids for longer than 3 months)
  • However, patients using chronic opioids may enroll in a parallel pilot study entitled 'effect of duloxetine on opioid use after total knee athroplasty among patients exposed to opioids- a pilot study'. The chronic opioid users will be allowed to continue their customary analgesics. The pilot study is otherwise identical to the main study.
  • This study will enroll up to 15 chronic opioid users. After that, all chronic opioid users are excluded.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03271151). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search